Page 41 - 2017 V1 InsideOut

ClinicalTrials
The latest research making therapies available to patients.
Genentech is sponsoring a Phase I, open label, open-study dose-escalation study of DMUC4064A administered by intravenous (IV) infusion every three weeks to cancer patients. The study will employ a traditional 3 + 3 dose escala- tion design to determine the maximum tolerated dose of DMUC4064A against platinum-resistant ovarian cancer. Eligibility requirements include, but
are not limited to, patients 18 years and older with histological documentation of epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer. Estimated study completion is December 2017. NCT02146313
Indiana University, in collaboration with the National Institute on Aging, is conducting an Alzheimer’s disease genetics study to identify the genes that are responsible for causing Alzheimer’s Disease (AD). One of the ways in which the risk factor genes for late onset AD can be investigated is by identifying and collecting genetic material from families with multiple members diagnosed with
AD or dementia. Eligibility requirements include, but are not limited to, families (including children, adults and seniors) with two or more members with AD or dementia. Estimated study completion is July 2021. NCT00064870
James F. Chmiel, in collaboration with Case Western Reserve University and the Cystic Fibrosis Foundation Therapeutics, is conducting a Phase I, single center, open label, single dose, dose escalation study assessing the safety and tolerability of allogeneic mesenchymal stem cell infusion in adults with cystic brosis (CF). Eligibility requirements include, but are not limited to, patients 18 to 40 years of age with confirmed diagnosis
of CF as evidenced by one or more clinical features consistent with the CF phenotype. Estimated study completion is August 2020. NCT02866721
Janssen Scienti c Affairs, LLC, is conducting a comparative and pragmatic study of golimumab intravenous (IV) versus biosimilar infliximab in patients
with Rheumatoid arthritis (RA). The study allows for an anticipated 2-year enrollment period and a 3-year study duration for each patient. Eligibility requirements include, but are not limited to, patients 18 years and older. Patients in the U.S. who enroll in the study will have a rheumatologist confirmed diagnosis of RA and will be medically eligible for, and will have been prescribed but not yet initiated treatment with, golimumab IV or infliximab. Estimated study completion is February 2021. NCT02728934
Massachusetts General Hospital, in collaboration with the National Cancer Institute, is conducting a research study using FMISO-PET and MRI scans to explore the delivery of bevacizumab
to the blood vessels in patients with recurrent glioblastoma before and after treatment. Eligibility requirements include, but are not limited to, patients 18 years and older with histologically confirmed glioblastoma and evidence of recurrence. Estimated study completion is January 2019. NCT02076152
University of North Carolina, Chapel Hill, in collaboration with
the National Institute of Neurological Disorders and Stroke, is sponsoring a pilot clinical trial to assess the ability
of a new ultrasound-based imaging method, Double-Push Acoustic Radiation Force (DP ARF) ultrasound, to monitor the progression of muscle degeneration in Duchenne muscular dystrophy. Eligibility requirements include, but are not limited to, male children ages five to 13 with clinical diagnosis of Duchenne muscular dystrophy with clinical onset by age five. Estimated study completion is September 2018. NCT01506518
To get information quickly
on the studies, access
Tip! ClinicalTrials.gov and type in the identifier
number.
i.e., NCT01850004
ASD Healthcare | 37